

SYNTHESIS OF SOME NEW QUINOXALINE DERIVATIVES FOR BIOLOGICAL EVALUATION

Thesis
Presented By

Shada Hassan Yassin

Assist. Lecturer of Medicinal Chemistry
Faculty of Pharmacy-Sana'a University

For the Requirements of
The Degree of Doctor of Philosophy in Pharmaceutical
Sciences in Medicinal Chemistry

Under the Supervision of

Prof. Dr.
Mohamed E. El-Sadek

Prof. of Medicinal Chemistry
Medicinal Chemistry Dept.
Faculty of Pharmacy
Zagazig University

Prof. Dr.
El-Sayed M. Lashine

Prof. of Medicinal Chemistry
Medicinal Chemistry Dept.
Faculty of Pharmacy
Zagazig University

Dr.
Osama I. El-Sabbagh

Ass. Prof. of Medicinal Chemistry
Medicinal Chemistry Dept.
Faculty of Pharmacy
Zagazig University

Faculty of Pharmacy
Zagazig University
2008

تشديد بعض مشتقات الكينوأوكساليين الجديدة لتقييمها بيولوجياً

رسالة مقدمة من

شذى حسن ياسين

المدرس المساعد بقسم الكيمياء الطبية
كلية الصيدلة - جامعة صنعاء
الجمهورية اليمنية

للحصول على

درجة دكتوراه الفلسفة في العلوم الصيدلانية

(الكيمياء الطبية)

تحت إشرافه

الأستاذ الدكتور

السيد محمد منصور لاشين

أستاذ الكيمياء الطبية
كلية الصيدلة - جامعة الزقازيق

الأستاذ الدكتور

محمد الحسيني الصادق

أستاذ الكيمياء الطبية
كلية الصيدلة - جامعة الزقازيق

الدكتور

أسامة إبراهيم الصباغ

أستاذ مساعد الكيمياء الطبية
كلية الصيدلة - جامعة الزقازيق

كلية الصيدلة

جامعة الزقازيق

٢٠٠٨

Dedication

This Thesis is Dedicated to:

The Soil of My Parents

My Husband Prof. Dr. Magdi Aqlan

My Daughter, Rasha and

My Son, Hassan,

All those who love me

Shada Hassan Yassin

ABSTRACT

In the present investigation, one known starting materials, five novel intermediates and thirty eight novel final compounds of 2(1H)-quinoxalinone derivatives were synthesized. Several new 2(1H)-quinoxalinone derivatives were prepared with the aim to have antibacterial and anti-inflammatory activities.

Accordingly, to obtain such derivatives, the following routes were adopted:

- 1- Cyclocondensation of equimolar amounts of 1,2-cyclohexandiamine with ethyl pyruvate or diethyl oxalacetate in ethanol containing catalytic amounts of glacial acetic acid afforded the desired synthon 3-methyl-4a,5,6,7,8,8a-hexahydro-2(1H) quinoxalinone (**I**) or its ethyl ester derivative (**III_b**). Similarly, the reaction of 1,2-benzenediamine with diethyl oxaloacetate gave the corresponding unsaturated ethyl ester derivative (**III_a**).
 - 2- The novel 3-((2-(4-Substitutedphenyl)hydrazono) methyl) 4a,5,6,7,8,8a-hexahydroquinoxalin-2(1H)-ones (**II_{a-h}**) were obtained in 70-90 % yields through coupling of the appropriate diazonium salt, of different aromatic amines (37% HCl and NaNO₂) with 3-methyl-4a,5,6,7,8,8a-hexahydro-2(1H)-quinoxalinone (**I**) in acetic acid buffered with sodium acetate at 0°C with intermittent stirring for 24 hrs.
 - 3- Condensation of the ester (**III_{a,b}**) with hydrazine hydrate in hot ethanol afforded the novel 2-(2-Oxo-1,2-dihydroquinoxalin-3-yl)acetohydrazide and its 1,2,4a,5, 6,7,8,8a-octahydro derivative(**IV_{a,b}**).
 - 4- These hydrazides (**IV_{a,b}**) were condensed with succinic or phthalic anhydride in refluxing acetic acid to afford the new dioxopyrrolidine or
-

dioxoisindoline (**V_{a,b}**) and their octahydro derivatives (**VI_{a,b}**).

- 5- Moreover, the unsaturated acid hydrazide (**IV_a**) was stirred with the appropriate acid chloride in acetic acid/sodium acetate at room temperature for 12 hrs to afford the new 3-(4-substituted benzoylhydrazinocarbonylmethyl)-2(1H)-quinoxalinone (**VII_{a-c}**).
- 6- The reaction of the two acid hydrazides (**IV_{a,b}**) and the appropriate isothiocyanate in refluxing ethanol for 2 hrs afforded the novel thiosemicarbazides (**VIII_{a-c}**) and their octahydro derivatives (**VIII_{d-f}**).
- 7- Cyclization of the thiosemicarbazides (**VIII_{a-c}**) was conducted in 2N NaOH by heating under reflux for 2 hrs to afford the novel 5-mercapto-4-substituted-4H-1,2,4-triazole derivatives (**IX_{a-c}**).
- 8- Furthermore, the playmaker acid hydrazide (**IV_a**) was condensed with different aromatic aldehydes in hot ethanol containing catalytic amounts of acetic acid to give the novel benzylidene derivatives (**X_{a-i}**).
- 9- This acid hydrazide (**IV_a**) could be reacted with carbon disulphide in the presence of potassium hydroxide either in hot ethanolic solution to give the novel oxadiazole (**XI**) or by cooling these reactants and stirring at room temperature for 14 hrs to afford the intermediate potassium salt of dithiocarbazate (**XII**).
- 10- This potassium salt intermediate could be cyclized using either hydrazine hydrate in refluxing ethanol to obtain the novel 4-amino-5-mercapto-4H-1,2,4-triazole (**XIII**) or substituted phenacyl bromides in situ and stirring reactants in dioxane at room temperature for 12 hrs to afford the novel thiazole derivatives (**XIV_{a-c}**).

The purity of the newly synthesized compounds was checked by TLC, and the structures of these compounds were confirmed by elemental

microanalyses and most of them were studied by different spectroscopic methods.

The rationale behind the synthesis of these compounds, their methods of syntheses as well as their antibacterial and anti-inflammatory activities were discussed. In this thesis the following compounds were prepared:

Known starting materials:

- 1) 3-(Ethoxycarbonylmethyl)-2(1H)-quinoxalinone (**III_a**)

Novel intermediates:

- 1) 3-Methyl-4a,5,6,7,8,8a-hexahydro-2(1H)-quinoxalinone(**I**)
- 2) 3-(Ethoxycarbonylmethyl)- 1,2,,4a,5,6,7,8 , 8a-octahydro-2-quinoxalinone (**III_b**)
- 3) 2-(2-Oxo-1,2-dihydroquinoxalin-3-yl)acetohydrazide (**IV_a**)
- 4) 2-(2-Oxo-1,2,4a,5, 6,7,8,8a-octahydroquinoxalin-3-yl)acetohydrazide (**IV_b**)
- 5) Potassium,3-[2-(2-oxo-1,2-dihydroquinoxalin-3-yl)acetyl]dithiocarbazate (**XII**)

Novel final compounds:

- 1) 3-((2-(phenyl)hydrazono)methyl)4a,5,6,7,8,8a-hexahydro quinoxalin-2(1H)-one (**II_a**)
 - 2) 3-((2-(4-Chlorophenyl)hydrazono)methyl)4a,5,6,7,8,8a-hexahydro quinoxalin-2(1H)-one (**II_b**)
 - 3) 3-((2-(3-Chlorophenyl)hydrazono)methyl)4a,5,6,7,8,8a-hexahydro quinoxalin-2(1H)-one (**II_c**)
-

-
- 4) 3-((2-(4-Bromophenyl)hydrazono)methyl)4a,5,6,7,8,8a-hexahydro quinoxalin-2(1H)-one (**II_d**)
 - 5) 3-((2-(3-Bromophenyl)hydrazono)methyl)4a,5,6,7,8,8a-hexahydro quinoxalin-2(1H)-one (**II_e**)
 - 6) 3-((2-(4-Fluoro phenyl)hydrazono)methyl)4a,5,6,7,8,8a-hexahydro quinoxalin-2(1H)-one (**II_f**)
 - 7) 3-((2-(2-Fluorophenyl)hydrazono)methyl)4a,5,6,7,8,8a-hexahydro quinoxalin-2(1H)-one (**II_g**)
 - 8) 3-((2-(4-Methylphenyl)hydrazono)methyl)4a,5,6,7,8,8a-hexahydro quinoxalin-2(1H)-one(**II_h**)
 - 9) 3-[(2,5-Dioxopyrrolidin-1-yl)aminocarbonylmethyl]-2(1H)-quinoxalinone (**V_a**)
 - 10) 3-[(1,3--Dioxoisindolin-2-yl)aminocarbonylmethyl]-2(1H)-quinoxalinone (**V_b**)
 - 11) 3-[(2,5-Dioxopyrrolidin-1-yl)aminocarbonylmethyl]-1,2,4a,5,6,7,8,8a-octahydro-2-quinoxalinone (**VI_a**)
 - 12) 3-[(1,3--Dioxoisindolin-2-yl)aminocarbonylmethyl]-1,2,4a,5,6,7,8,8a-octahydro-2-quinoxalinone (**VI_b**)
 - 13) 3-(Benzoylhydrazinocarbonylmethyl)-2(1H)-quinoxalinone (**VII_a**)
 - 14) 3-(4-Chlorobenzoylhydrazinocarbonylmethyl)-2(1H)-quinoxalinone (**VII_b**)
 - 15) 3-(4-Methylbenzoylhydrazinocarbonylmethyl)-2(1H)-quinoxalinone (**VII_c**)
 - 16) N¹-[(2-Oxo-1,2-dihydroquinoxalin-3-yl)methylcarbonyl]-N⁴-phenylthiosemicarbazide (**VIII_a**)
-

-
- 17) N^1 -[(2-Oxo-1,2-dihydroquinoxalin-3-yl)methylcarbonyl]- N^4 -ethyl thiosemicarbazide (**VIII_b**)
 - 18) N^1 -[(2-Oxo-1,2-dihydroquinoxalin-3-yl)methylcarbonyl]- N^4 -allyl thiosemicarbazide (**VIII_c**)
 - 19) N^1 -[(2-Oxo-1,2,4a,5,6,7,8,8a-octahydroquinoxalin-3-yl)methyl carbonyl]- N^4 - phenylthiosemicarbazide (**VIII_d**)
 - 20) N^1 -[(2-Oxo-1,2,4a,5,6,7,8,8a-octahydroquinoxalin-3-yl)methyl carbonyl]- N^4 - ethyl thiosemicarbazide (**VIII_e**)
 - 21) N^1 -[(2-Oxo-1,2,4a,5,6,7,8,8a-octahydroquinoxalin-3-yl)methyl carbonyl]- N^4 -allylthiosemicarbazide (**VIII_f**)
 - 22) 3-((5-Mercapto-4-phenyl-4H-1,2,4-triazol-3-yl)methyl)-2(1H)-quinoxalinone (**IX_a**)
 - 23) 3-((5-Mercapto-4-ethyl-4H-1,2,4-triazol-3-yl)methyl)-2(1H)-quinoxalinone (**IX_b**)
 - 24) 3-((5-Mercapto-4-allyl-4H-1,2,4-triazol-3-yl)methyl)-2(1H)-quinoxalinone (**IX_c**)
 - 25) 3-(Benzylidenehydrazinocarbonylmethyl)-2(1H)-quinoxalinone(**X_a**)
 - 26) 3-(4-Hydroxybenzylidenehydrazinocarbonylmethyl)-2(1H)-quinoxalinone(**X_b**)
 - 27) 3-(4-Bromobenzylidenehydrazinocarbonylmethyl)-2(1H)-quinoxalinone (**X_c**)
 - 28) 3-(4-Chlorobenzylidenehydrazinocarbonylmethyl)-2(1H)-quinoxalinone (**X_d**)
 - 29) 3-(4-Nitrobenzylidenehydrazinocarbonylmethyl)-2(1H)-quinoxalinone (**X_e**)
-

-
- 30) 3-(4-Methoxybenzylidenehydrazinocarbonylmethyl)-2(1H)-quinoxalinone (**X_f**)
- 31) 3-(2,4-Dichlorobenzylidenehydrazinocarbonylmethyl)-2(1H)-quinoxalinone(**X_g**)
- 32) 3-(4-Methylbenzylidenehydrazinocarbonylmethyl)-2(1H)-quinoxalinone(**X_h**)
- 33) 3-(4-Fluorobenzylidenehydrazinocarbonylmethyl)-2(1H)-quinoxalinone(**X_i**)
- 34) 3-((5-Mercapto-1,3,4-oxadiazol-2-yl)methyl)-2(1H)-quinoxalinone (**XI**)
- 35) 3-((4-Amino-5-mercapto-4H-1,2,4-triazol-3-yl)methyl)-2(1H)-quinoxalinone (**XIII**)
- 36) 3-[N-(4-Phenyl-2-thioxo-2,3-dihydrothiazol-3-yl)aminocarbonylmethyl]-2(1H)-quinoxalinone(**XIV_a**)
- 37) 3-[N-(4-Chlorophenyl -2-thioxo-2,3-dihydrothiazol-3-yl)aminocarbonylmethyl]-2(1H)-quinoxalinone **XIV_b**)
- 38) 3-[N-(4-Methylphenyl-2-thioxo-2,3-dihydrothiazol-3-yl)aminocarbonylmethyl]-2(1H)-quinoxalinone (**XIV_c**)

Finally, some novel 2(1H)-quinoxalinone derivatives were subjected to biological evaluation to study their *in vitro* antimicrobial activity using cup-plate technique and also their *in vivo* anti-inflammatory activity was determined using the rat hind paw oedema method.

The preliminary antimicrobial activity for some new 2(1H)-quinoxalinone derivatives revealed that the hydrazono of hexahydro-2(1H)-quinoxalinones derivatives (**II_{b,f}**) containing halogen showed a high activity

against Gram-positive both cocci and bacilli which were comparable to the reference drug (ciprofloxacin). Moreover, the saturated octahydro thiosemicarbazide derivatives (**VIII_{d,f}**) showed a higher activity than their corresponding unsaturated ones (**VIII_{a,c}**) whereas the octahydro thiosemicarbazide **VIII_d** bearing a phenyl moiety has nearly the same activity as the reference drug ciprofloxacin against both Gram-positive and Gram-negative bacteria. All the tested compounds have no antifungal activity.

Some novel compounds **IX_a**, **IX_b**, **XI**, **XIII**, **XIV_a**, **XIV_b** and **XIV_c** were evaluated *in vivo* for their anti-inflammatory activities at a dose of 0.9mg/100gm body weight into mature male albino rats using the rat hind paw oedema method, in addition, their ulcerogenic activity was determined using celecoxib and indomethacin as references drugs. It was observed that the quinoxalinone derivatives bearing 4-chlorophenylthiazole (**XIV_b**) and the 4-phenyltriazole (**IX_a**) moieties showed a higher antiinflammatory activity than reference drug celecoxib with no ulcerogenic activity.

AKNOWLEDGMENT

Firstly, I am deeply thankful to the Almighty Allah (SWT), by the grace of whom the progress and success of this work was possible.

*I wish to express my sincere and deep gratitude to **Prof. Dr. Mohamed E. El-Sadek**, Professor of Medicinal Chemistry, Faculty of Pharmacy, Zagazig University, for his fruitful discussion, continuous assistance, encouragement, close supervision, keen support and solving the scientific problems I faced during performing this work.*

*I am greatly thankful to **Prof. Dr. El-Sayed Lashine**, Professor of Medicinal Chemistry, Faculty of Pharmacy, Zagazig University, for his expert guidance, constructive criticism, and also for his continuous encouragement, valuable suggestions, great help, advice and cooperation throughout my research project.*

*I wish to express my cordial thanks and respect to **Dr. Osama I. El-Sabbagh**, Assist. Prof. of Medicinal Chemistry, Faculty of Pharmacy, Zagazig University for supervising this work and his continual follow-up from the beginning to the end of this research project.*

*I wish also to express my thanks to **Dr. Sameh M. El-Nabtity** Assist. Prof. of Pharmacology, Faculty of Veterinary medicine, Zagazig University, for performing the pharmacological part.*

*I wish also to express my deep gratitude to **Dr. Moamen Mahmoud Ez-Alarab**, Assist. Lecturer of Microbiology, Faculty of Pharmacy, Zagazig University, for performing the antimicrobial activity.*

I would like to express my thanks to the whole staff and assistants in Medicinal Chemistry Department, Faculty of Pharmacy, Zagazig University.

Finally, I would like to express my sincere thanks to my parents, my husband Prof. Dr. Magdi Aqlan, my daughter Rasha, my son Hassan for their encouragement, enthusiasm, faith and emotional support that made this work possible. I really would not be able to complete this work without them.

Shada Hassan Yassin

CONTENTS

	Page
Chapter (1): Introduction	
Chemistry of quinoxalines	1
Synthesis of 2(1H)-quinoxalinones	1
1-Condensation of 1,2-diamino compounds with 1,2-bis-electrophiles. 1	
2- Intramolecular aminolysis of N-(2-aminoethyl)- <i>o</i> -halogenoanilines. 5	
3-Dehydrogenation of 1,2,3,4-tetrahydro-quinoxaline-2-ones	5
4-Nucleophilic substitution of 2-amino-3-substituted-quinoxaline	6
5- Synthesis based on additional reactions	6
6- Using a diamide (oxamide), amido nitrile, or related synthon	7
7-Reductive cyclization of <i>o</i> -(substitutedamino)	
nitrobenzene derivatives.....	8
8- Using other heteromonocyclic substrates	9
The chemical behaviour of 2(1H)-quinoxalinones	13
The tautomerism of 2(1H)-quinoxalinones.....	13
Reactions of tautomeric quinoxalinones	13
1- Alkylation	13
2) Halogenation	15
3) Direct thiation	18
4) Nuclear oxidative reactions	18
5) Reductive deoxygenation.....	18
6) Hydrazinolysis	19
7) Conversion into semicarbazidoquinoxalines	19
8) Reactivity of 3-alkyl derivatives of 2(1H)-quinoxalinone	20
9) The cyclization reactions of 2(1H) quinoxalinones.....	23

Biological Activity of Quinoxalines	26
1) Hypoglycemic activity	26
2) Antiglaucoma activity	27
3) Antineoplastic activity	27
4) Antiviral activity	29
5) Anti-inflammatory activity	30
6) Antibacterial activity	31
7) Antifungal activity	35
8) CNS depressant activity	37
Chapter (2): Research Objectives	38
Scheme 1	42
Scheme 2	43
Scheme 3	44
Scheme 4	45
Scheme 5	46
Chapter (3): Discussion and Results	47
3-methyl-4a,5,6,7,8,8a-hexahydro-2(1H) quinoxalinone (I)	47
3-((2-(Substitutedphenyl)hydrazono)methyl)-4a,5,6,7,8,8a-hexahydroquinoxalin-2(1H)-one (II _{a-h})	48
3-(Ethoxycarbonylmethyl)-2(1H)-quinoxalinone and its 4a,5,6,7,8, 8a-hexahydro derivative (III _{a,b})	50
2-(2-Oxo-1,2-dihydroquinoxalin-3-yl)acetohydrazide and its 1,2,4a,5, 6,7,8,8a-octahydro derivative(IV _{a,b})	52
3-[(2,5-Dioxopyrrolidin-1-yl)aminocarbonylmethyl]-2(1H)- quinoxalinone and 3-[(1,3--dioxoisindolin-2-yl)amino carbonylmethyl]-2(1H)quinoxalinone(V _{a,b}) and their 4a,5,6,7,8, 8a-hexahydro derivatives (VI _{a,b})	53

3-(4-Substitutedbenzoylhydrazinocarbonylmethyl)-2(1H)-quinoxalinone(VII _{a-c})	53
N ¹ -[(2-Oxo-1,2-dihydroquinoxalin-3-yl)methylcarbonyl]-N ⁴ -substituted thiosemicarbazide and their 1,2,4a,5,6,7,8,8a-octahydro derivatives (VIII _{a-f})	54
3-((5-Mercapto-4-substituted-4H-1,2,4-triazol-3-yl)methyl)-2(1H)-quinoxalinones(IX _{a-c})	55
3-(Substitutedbenzylidenehydrazinocarbonylmethyl)-2(1H)-quinoxalinones(X _{a-i})	56
3-(5-Mercapto-1,3,4-oxadiazol-2-yl)methyl)-2(1H)-quinoxalinone(XI)	57
Potassium,3-[2-(2-oxo-1,2-dihydroquinoxalin-3-yl) acetyl]dithiocarbazate (XII)	59
3-((4-Amino-5-mercapto-4H-1,2,4-triazol-3-yl)methyl)-2(1H)-quinoxalinone(XIII)	60
4-Substituted phenacyl bromides	63
3-[N-(4-Substitutedphenyl-2-thioxo-2,3-dihydrothiazol-3-yl)aminocarbonylmethyl]-2(1H)-quinoxalinones(XIV _{a-c}).....	63
Chapter (4): Experimental	65
3-methyl-4a,5,6,7,8,8a-hexahydro-2(1H) quinoxalinone (I)	66
3-((2-(Substitutedphenyl)hydrazono)methyl)-4a,5,6,7,8,8a-hexahydroquinoxalin-2(1H)-ones (II _{a-h})	67
3-(Ethoxycarbonylmethyl)-2(1H)-quinoxalinone and its 4a,5,6,7,8 , 8a-hexahydro derivatives (III _{a,b}).....	70
2-(2-Oxo-1,2-dihydroquinoxalin-3-yl)acetohydrazide and its 1,2,4a,5, 6,7,8,8a-octahydro derivative(IV _{a,b})	72
3-[(2,5-Dioxopyrrolidin-1-yl)aminocarbonylmethyl]-2(1H) -quinoxalinone	

and 3-[(1,3--dioxoisindolin-2-yl)aminocarbonylmethyl]-2(1H)quinoxal inone(V _{a,b}) and their 4a,5,6,7,8, 8a-hexahydro derivatives (VI _{a,b})	73
3-(4-Substitutedbenzoylhydrazinocarbonylmethyl)-2(1H)-quinoxalin one(VII _{a-c}).....	77
N ¹ -[(2-Oxo-1,2-dihydroquinoxalin-3-yl)methylcarbonyl]-N ⁴ - substituted thiosemicarbazide and their 1,2,4a,5,6,7,8,8a- octahydro derivatives (VIII _{a-f}).....	79
3-((5-Mercapto-4-substituted-4H-1,2,4-triazol-3-yl)methyl)-2(1H)- quinoxalinone(IX _{a-c})	83
3-(Substitutedbenzylidenehydrazinocarbonylmethyl)-2(1H)- quinoxalinone(X _{a-i})	86
3-((5-Mercapto-1,3,4-oxadiazol-2-yl)methyl)-2(1H)- quinoxalinone(XI)	89
Potassium,3-[2-(2-oxo-1,2-dihydroquinoxalin-3-yl)acetyl]dithiocarbazate (XII).....	91
3-((4-Amino-5-mercapto-4H-1,2,4-triazol-3-yl)methyl)-2(1H)- quinoxalinone(XIII)	92
4- Substituted phenacyl bromides	94
3-[N-(4-Substitutedphenyl-2-thioxo-2,3-dihydrothiazol-3-yl) aminocarbonylmethyl]-2(1H)-quinoxalinone(XIV _{a-c})	95
Chapter (5): Biological activity	98
A) Antimicrobial activity	98
B) Pharmacology	101
Antiinflammatory activity evaluation	101
Ulcerogenic activity	101
Chapter (6): References	106
Arabic Summary	